Redesign Science - AlleyWatch
Redesign Science is a computational chemistry company setting a new standard for early-stage, small molecule drug discovery. Founded by David Rooklin and Haotian Li in 2017, Redesign Science is backed by investors that include Morningside Venture Capital, Notation Capital, Refactor Capital, Third Kind Venture Capital, and Thomas Weingarten and is headquartered in New York.
Source: alleywatch.com